REAL TIME GENE QUANTIFICATION WITH INTERNAL STANDARDS
Not Available Tera Biotechnology Corporation proposes to develop an automated system to screen phage antibody libraries by our parallel selection process. The system we propose could be used to routinely generate antibodies of any specificity without the need for human intervention. For Phase I we will develop an automated robotic system for the identification and selection of specific antibodies that bind ovalbumin, a biological warfare simulant. Our goal in Phase II will be to produce and test an efficient automated screening system, compatible with use at P4 biosafety levels, for the cloning of antibody binding fragments useful for the detection of novel biological warfare agents. BENEFITS: Current protocols used to discover antibodies to bioagents are cumbersome and may expose personnel to risk. To lower the risk to personnel and to generate considerable cost savings an automated method to clone high affinity antibodies is highly desirable.
Small Business Information at Submission:
Principal Investigator:Randy P. Rasmussen
390 WAKARA WAY SALT LAKE CITY, UT 84108
Number of Employees: